Article Dans Une Revue Cancers Année : 2022

Histone Deacetylase Functions in Gastric Cancer: Therapeutic Target?

Résumé

Gastric cancer (GC) is one of the most aggressive cancers. Therapeutic treatments are based on surgery combined with chemotherapy using a combination of platinum-based agents. However, at metastatic stages of the disease, survival is extremely low due to late diagnosis and resistance mechanisms to chemotherapies. The development of new classifications has not yet identified new prognostic markers for clinical use. The studies of epigenetic processes highlighted the implication of histone acetylation status, regulated by histone acetyltransferases (HATs) and by histone deacetylases (HDACs), in cancer development. In this way, inhibitors of HDACs (HDACis) have been developed and some of them have already been clinically approved to treat T-cell lymphoma and multiple myeloma. In this review, we summarize the regulations and functions of eighteen HDACs in GC, describing their known targets, involved cellular processes, associated clinicopathological features, and impact on survival of patients. Additionally, we resume the in vitro, pre-clinical, and clinical trials of four HDACis approved by Food and Drug Administration (FDA) in cancers in the context of GC.

Fichier principal
Vignette du fichier
cancers-14-05472-v2.pdf (734.79 Ko) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)
Licence

Dates et versions

inserm-05281008 , version 1 (24-09-2025)

Licence

Identifiants

Citer

Amandine Badie, Christian Gaiddon, Georg Mellitzer. Histone Deacetylase Functions in Gastric Cancer: Therapeutic Target?. Cancers, 2022, 14 (21), pp.5472. ⟨10.3390/cancers14215472⟩. ⟨inserm-05281008⟩
791 Consultations
72 Téléchargements

Altmetric

Partager

  • More